At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
LDN +1 moredrug
Likely dose
LDN 4.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
In Brief
A Phase 2 clinical trial evaluating LDN and Placebo for Malignant Glioma. Completed, enrolled 110 participants across 1 site.
Detailed Summary
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionJun 2014
Study CompletionMay 2015
TodayJul 2026
First PostedFeb 25, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.4 years ago
Interventions
LDNdrug
Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
Placebodrug
Randomized patients received placebo to be taken every night before bed.